Access our previous webinar recordings below!

Hear Florence and TruLab discuss best practices for site adoption of sponsor-provided technology and how best to accomodate site workflows. 

This webinar sought to address and dispel the most common myths surrounding clinical trial oversight, providing sponsors with the clarity and direction needed to navigate the complexities of their roles effectively.

Learn top site-centric insights Mark has learned from his experience that every sponsor must keep in mind to make their clinical trials more effective.

Our panel consisting of clinical experts discussed transforming vendor relationships into symbiotic partnerships.

Our panel consisting of seasoned clinical pharmacologists discussed challenges of early stage to late stage development.

Our panel consisting of former and current Clinical Research Coordinators discussed what defines source data and the miconceptions surrounding this topic. 

Our panel consisting of a Principal Investigator and a former Study Participant discussed how current practices in clinical trials magnify patient burden. 

Our panel consisting of veterans of the industry discussed the positive and negative nature of queries and their impacts on sites, sponsors, and sample logistics.
Our panelists discussed the prevalence of errors and impact of unusable samples, the importance of ethical considerations of the patients in the study design and sampling schema, and the regulatory impact of sample mishandling and loss
Our panelists discussed understanding different site workflows and how to design studies that take real-world workflows into account and what sponsors, CROs, and tech vendors can do to reduce site burden and provide a better experience for sites
Our panelists discussed how sample issues impact data quality for clinical pharmacological evaluations, the impact of queries on sites, and the importance of proper sample tracking to enable bioanalytical labs to run assays in a timely fashion

 

Our panelists discussed the issues revolving around increasingly complex protocols, no real-time visibility & study delays